JP2010522146A - タンパク質のカルボニル化の増加の予防およびそれを原因とする病変の治療のためのシトルリンの使用 - Google Patents

タンパク質のカルボニル化の増加の予防およびそれを原因とする病変の治療のためのシトルリンの使用 Download PDF

Info

Publication number
JP2010522146A
JP2010522146A JP2009554063A JP2009554063A JP2010522146A JP 2010522146 A JP2010522146 A JP 2010522146A JP 2009554063 A JP2009554063 A JP 2009554063A JP 2009554063 A JP2009554063 A JP 2009554063A JP 2010522146 A JP2010522146 A JP 2010522146A
Authority
JP
Japan
Prior art keywords
citrulline
treatment
composition
intended
nutrition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009554063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010522146A5 (enExample
Inventor
モナー，クリストフ
ワルランド，ステファン
ボワリ，イヴ
シノベール，ルク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Institut National de la Recherche Agronomique
Université Paris Descartes
Centre Hospitalier Universitaire de Clermont-Ferrand
Original Assignee
Assistance Publique - Hôpitaux de Paris
Institut National de la Recherche Agronomique
Université Paris Descartes
Centre Hospitalier Universitaire de Clermont-Ferrand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique - Hôpitaux de Paris, Institut National de la Recherche Agronomique, Université Paris Descartes, Centre Hospitalier Universitaire de Clermont-Ferrand filed Critical Assistance Publique - Hôpitaux de Paris
Publication of JP2010522146A publication Critical patent/JP2010522146A/ja
Publication of JP2010522146A5 publication Critical patent/JP2010522146A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
JP2009554063A 2007-03-22 2008-03-20 タンパク質のカルボニル化の増加の予防およびそれを原因とする病変の治療のためのシトルリンの使用 Pending JP2010522146A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702090A FR2913885B1 (fr) 2007-03-22 2007-03-22 Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
PCT/FR2008/000379 WO2008135661A2 (fr) 2007-03-22 2008-03-20 Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines

Publications (2)

Publication Number Publication Date
JP2010522146A true JP2010522146A (ja) 2010-07-01
JP2010522146A5 JP2010522146A5 (enExample) 2011-05-06

Family

ID=38561836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009554063A Pending JP2010522146A (ja) 2007-03-22 2008-03-20 タンパク質のカルボニル化の増加の予防およびそれを原因とする病変の治療のためのシトルリンの使用

Country Status (8)

Country Link
US (1) US20100093863A1 (enExample)
EP (1) EP2136777A2 (enExample)
JP (1) JP2010522146A (enExample)
CN (1) CN101686919A (enExample)
CA (1) CA2689608A1 (enExample)
FR (1) FR2913885B1 (enExample)
IL (1) IL200830A0 (enExample)
WO (1) WO2008135661A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017057610A1 (ja) * 2015-09-29 2017-04-06 協和発酵バイオ株式会社 経口組成物
WO2024147532A1 (ko) * 2023-01-05 2024-07-11 주식회사 마이크로엑스 패혈증의 예방, 개선 또는 치료용 조성물

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600260A (zh) * 2010-12-24 2012-07-25 漆又毛 一种氨基酸和提取物组合物防治老年性痴呆的药物用途
EP2685987B1 (en) * 2011-03-18 2019-04-24 Nestec S.A. Compositions and methods useful for ameliorating age related maladies
JP2014512372A (ja) * 2011-04-18 2014-05-22 ネステク ソシエテ アノニム α−ＨＩＣＡ及びエイコサペンタエン酸を含有する栄養組成物
WO2014125376A2 (en) * 2013-02-15 2014-08-21 Mediterranean Institute For Life Sciences Protein damage in aging and age-related diseases
CN106137782A (zh) * 2015-04-22 2016-11-23 捷通国际有限公司 包含青藤碱的局部组合物及用于抑制蛋白羰基化的方法
CN105147684B (zh) * 2015-09-30 2017-12-12 暨南大学 胡椒碱在制备防治败血症药物中的应用

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2691359A1 (fr) * 1992-05-20 1993-11-26 Krempf Michel Nouvelle application thérapeutique du Malate de 1-Citrulline.
JPH09505822A (ja) * 1993-12-02 1997-06-10 バイヤースドルフ・アクチエンゲゼルシヤフト Ｌ−アルギニン、ｌ−オルニチン又はｌ−シトルリン及びこれらの物質の局所用調製物類の使用
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
JP2002226370A (ja) * 2001-02-05 2002-08-14 Nara Institute Of Science & Technology シトルリンを含有する活性酸素消去剤
JP2003522136A (ja) * 2000-02-14 2003-07-22 フリースランド・ブランズ・ビー・ブイ 腸壁の透過性亢進または望まれない透過性の治療または予防のための栄養学的または薬学的調製物の製造のためのグルタメートおよび／またはグルタメート前駆体の使用
WO2005002567A1 (en) * 2003-07-01 2005-01-13 Essentys Ab Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition
JP2005247700A (ja) * 2004-03-01 2005-09-15 Pias Arise Kk 活性酸素抑制用の組成物と、その組成物を配合する皮膚外用剤及び化粧料
WO2005115371A1 (fr) * 2004-04-29 2005-12-08 Universite Rene Descartes-Paris 5 Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
JP2006503105A (ja) * 2002-09-20 2006-01-26 ノバルティス アクチエンゲゼルシャフト ロイシンに富んだ栄養的組成物
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
JP2006124327A (ja) * 2004-10-28 2006-05-18 Fancl Corp 異常蛋白質除去用組成物
WO2007023931A1 (ja) * 2005-08-25 2007-03-01 Kyowa Hakko Kogyo Co., Ltd. 血中アルコール濃度上昇抑制用組成物
JP2009533342A (ja) * 2006-04-04 2009-09-17 ネステク ソシエテ アノニム シトルリンを使用する治療
JP2010506887A (ja) * 2006-10-17 2010-03-04 ユニヴェルシテ パリ デカルト 栄養不足状態の治療のためのシトルリンの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
FR2766712B1 (fr) * 1997-08-01 1999-10-22 Aguettant Lab Composition de preference solution antioxydante et medicaments en faisant application
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
DE19929993C2 (de) * 1999-06-30 2001-07-05 Sueddeutsche Kalkstickstoff Kreatin-alpha-ketoglutarate, Verfahren zu ihrer Herstellung und ihre Verwendung
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2853210B1 (fr) * 2003-04-02 2006-12-15 Neolait Sas Composition activateur de la digestion
FR2857262B1 (fr) * 2003-07-08 2007-10-05 Biocodex Lab Utilisation de la citrulline dans le cadre de l'insuffisance intestinale
JP4887499B2 (ja) * 2004-04-30 2012-02-29 国立大学法人 奈良先端科学技術大学院大学 野生種スイカ抽出物を含有する活性酸素消去剤ならびに保湿剤
WO2006131054A1 (en) * 2005-06-04 2006-12-14 Zichun Li Chinese pharmaceutical ophthalmological formulations in forms of solutions, ointments and pills for antiaging recovery

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2691359A1 (fr) * 1992-05-20 1993-11-26 Krempf Michel Nouvelle application thérapeutique du Malate de 1-Citrulline.
JPH09505822A (ja) * 1993-12-02 1997-06-10 バイヤースドルフ・アクチエンゲゼルシヤフト Ｌ−アルギニン、ｌ−オルニチン又はｌ−シトルリン及びこれらの物質の局所用調製物類の使用
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
JP2003522136A (ja) * 2000-02-14 2003-07-22 フリースランド・ブランズ・ビー・ブイ 腸壁の透過性亢進または望まれない透過性の治療または予防のための栄養学的または薬学的調製物の製造のためのグルタメートおよび／またはグルタメート前駆体の使用
JP2002226370A (ja) * 2001-02-05 2002-08-14 Nara Institute Of Science & Technology シトルリンを含有する活性酸素消去剤
JP2006503105A (ja) * 2002-09-20 2006-01-26 ノバルティス アクチエンゲゼルシャフト ロイシンに富んだ栄養的組成物
WO2005002567A1 (en) * 2003-07-01 2005-01-13 Essentys Ab Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition
JP2005247700A (ja) * 2004-03-01 2005-09-15 Pias Arise Kk 活性酸素抑制用の組成物と、その組成物を配合する皮膚外用剤及び化粧料
WO2005115371A1 (fr) * 2004-04-29 2005-12-08 Universite Rene Descartes-Paris 5 Compositions pharmaceutiques pour la prevention et le traitement de l'atherosclerose
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
JP2006124327A (ja) * 2004-10-28 2006-05-18 Fancl Corp 異常蛋白質除去用組成物
WO2007023931A1 (ja) * 2005-08-25 2007-03-01 Kyowa Hakko Kogyo Co., Ltd. 血中アルコール濃度上昇抑制用組成物
JP2009533342A (ja) * 2006-04-04 2009-09-17 ネステク ソシエテ アノニム シトルリンを使用する治療
JP2010506887A (ja) * 2006-10-17 2010-03-04 ユニヴェルシテ パリ デカルト 栄養不足状態の治療のためのシトルリンの使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6013003510; 臨床医 Ｖｏｌ．１９，　Ｎｏ．３, 1993, ｐ．３７０-３７４ *
JPN6013003513; 日本内科学会雑誌 Ｖｏｌ．８８，Ｎｏ．２, 1999, ｐ．１５３-１６０ *
JPN6013003515; 生化学 Ｖｏｌ．７７，　Ｎｏ．２, 2005, ｐ．１４４-１４８ *
JPN6013003517; 日本未病システム学会雑誌 Ｖｏｌ．１０，　Ｎｏ．１, 2004, ｐ．１８-２０ *
JPN6013003519; Ｇｅｒｉａｔｒｉｃ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．４２，　Ｎｏ．８, 2004, ｐ．１０４３-１０４６ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017057610A1 (ja) * 2015-09-29 2017-04-06 協和発酵バイオ株式会社 経口組成物
JP2017066072A (ja) * 2015-09-29 2017-04-06 学校法人北里研究所 経口組成物
JP7220838B2 (ja) 2015-09-29 2023-02-13 学校法人北里研究所 経口組成物
WO2024147532A1 (ko) * 2023-01-05 2024-07-11 주식회사 마이크로엑스 패혈증의 예방, 개선 또는 치료용 조성물

Also Published As

Publication number Publication date
FR2913885A1 (fr) 2008-09-26
CA2689608A1 (fr) 2008-11-13
WO2008135661A2 (fr) 2008-11-13
IL200830A0 (en) 2010-05-17
WO2008135661A3 (fr) 2009-01-15
US20100093863A1 (en) 2010-04-15
FR2913885B1 (fr) 2012-07-20
CN101686919A (zh) 2010-03-31
EP2136777A2 (fr) 2009-12-30

Similar Documents

Publication Publication Date Title
JP7629432B2 (ja) グルタチオンレベルを改善するためのｎ－アセチルシステイン及びグリシンの補給の効果
Grimble Adverse gastrointestinal effects of arginine and related amino acids
US5866537A (en) Pharmaceutical and/or dietetic compositions with antioxidant activity containing carnosine or derivatives and branched amino acids
ES3057136T3 (en) Compositions comprising peptide wkdeagkplvk
JP3287842B2 (ja) 免疫刺激剤としてのアルギニンの用途
WO2010002242A1 (en) Nutritional composition for improving muscle function and daily activity
JP2022538154A (ja) 骨格筋における状態又は障害を予防又は治療するための、トリゴネリン及びビタミンを使用する組成物及び方法
US20100093863A1 (en) Use of citrulline for preventing an increase in protein carbonylation and for treating diseases resulting therefrom
EP3115047B1 (en) Debility preventative
EP2050444A1 (en) Fatigue-reducing agent
US20220241266A1 (en) Compositions and methods using trigonelline and high protein for preventing or treating conditions or disorders in skeletal muscle
US9480668B2 (en) Blood flow promoting agent
CN118900686A (zh) 增强一种或多种合成代谢氨基酸对骨健康的肌肉骨骼效应的组合物和方法
JP7410025B2 (ja) オートファジーの誘導のために高タンパク質を使用する組成物及び方法
JP2022538584A (ja) 骨格筋における状態又は障害を予防又は治療するための、トリゴネリン及びミネラルを使用する組成物及び方法
JP2010222284A (ja) 血中ｇｉｐ上昇抑制剤
CA3234362A1 (en) Compositions and methods using an autophagy inducer to enhance intermittent fasting
EP1807069B1 (en) Methods for regulating weight and size of animals with glycine
TW201818829A (zh) 酮體生成促進用組成物
US20120122984A1 (en) Methods of Treating Lipomas and Liposarcomas
JP2009001507A (ja) 体脂肪減少剤およびその利用
JP6053695B2 (ja) 食欲抑制剤
Farges et al. Oral administration of a glutamine-enriched diet before or after endotoxin challenge in aged rats has limited effects
JP5317456B2 (ja) 内因性オピオイドペプチドの血中分泌促進用組成物
KR20260069414A (ko) TGF-β1 및 FGF2 유전자 또는 단백질을 유효성분으로 포함하는, 괴사성 장염의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130628

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140204